ObjectiveTo explore the diagnostic value of resting-state functional magnetic resonance imaging (rs-fMRI) for mild cognitive impairment (MCI) stage of Alzheimer's disease (AD), and to investigate the changes in brain functional connectivity in default mode network (DMN) and medial temporal lobe (MTL) regions. MethodsLiteratures were retrieved from multiple databases including CNKI, PubMed, Medline, and Embase, etc. from January, 2020 to October, 2025, investigating the changes in functional connectivity of DMN and MTL in patients with MCI compared to health control (HC) using rs-fMRI. Two researchers independently screened and extracted the literatures and methodological quality was assessed using QUADAS-2. Review Manager 5.4 was used to perform a meta-analysis of neuroimaging indicators in MCI patients and HC subjects. Stata and SDM were utilized to summarize diagnostic efficacy and brain functional connectivity, calculating the over all sensitivity, specificity and summary receiver operating characteristic-area under the curve (SROC-AUC). Deeks funnel plots were drawn, literature weights were analyzed, and subgroup analyses were conducted. ResultsA total of ten literatures were ultimately included, involving 1 010 patients with MCI and 1 714 HC subjects. MCI patients showed decreased or abnormal blood oxygen level dependence signals in DMN, focusing on bilateral medial prefrontal cortex (mPFC) and posterior cingulate cortex. The SROC-AUC was 0.91. In MTL, there was a characteristic decrease of spontaneous neural functional connectivities between the hippocampus and other regions, reflecting the obstruction of information transmission from episodic memory to the central nodes. Abnormal functional connectivity in DMN and MTL resulted in compensatory resting-state functional connectivity enhancement in other subnetworks or local functional connections, such as frontoparietal network and the hippocampal-parietal network. Abnormal activation of mPFC suggested atrophy of the hippocampus or abnormal brain function. The decline in functional connectivity between DMN and MTL indicated impairment of memory and information processing in the early stage. ConclusionThe early functional decoupling between DMN and MTL is a crucial neural mechanism at the MCI stage of AD, providing important neuroimaging evidence for the early diagnosis of AD.

Objective To analyze the expression of vascular endothelial growth factor receptor-3(VEGFR3)and adaptor protein containing PH domain,PTB domain,and leucine zipper motif 1(APPL1)in non-small cell lung cancer(NSCLC)and their relationship with clinical pathology.Methods A total of 100 patients with NSCLC admitted to the First Affiliated Hospital of Bengbu Medical University from January 2019 to December 2020 were selected as the study objects,and the NSCLC tissues and adjacent tissues of the patients were collected.The expression of VEGFR3 and APPL1 was detected by immunohistochemistry,and the relationship between VEGFR3 and APPL1 expression and clinical pathology of patients was analyzed,as well as the predictive value of VEGFR3 and APPL1 for prognosis of patients with NSCLC.Results The posi-tive rates of VEGFR3 and APPL1 in NSCLC tissues and adjacent tissues were significantly different(P<0.05).The positive rate of VEGFR3 was significantly different in patients with different histological type,lymph node metastasis and tumor invasion(P<0.05).The positive rate of APPL1 was significantly different in patients with different histological type and tumor invasion(P<0.05).Spearman correlation analysis showed that VEGFR3 was positively correlated with APPL1 expression(r=0.330,P<0.05).The relative expression levels of VEGFR3 and APPL1 in death group were higher than those in survival group,and the difference was statistically significant(P<0.05).Receiver operating characteristic curve analysis showed that the area under the curve of relative expression levels of VEGFR3 and APPL1 to predict the prognosis of NSCLC patients was 0.843(95%CI:0.757-0.908)and 0.799(95%CI:0.707-0.872).Conclusion The ex-pression of VEGFR3 and APPL1 in NSCLC patients is related to their clinical pathological features.The relative ex-pression levels of VEGFR3 and APPL1 are of great value in predicting the prognosis of NSCLC patients.

Objective:To analyze the clinical features and prognosis of acute B lymphoblastic leukemia (B-ALL) children carrying a TCF3: : PBX1 fusion gene and to evaluate the prognostic value of this gene.Methods:Retrospective cohort study.A total of 2 164 B-ALL children aged 0-18 years diagnosed and treated at 19 pediatric centers from October 2016 to June 2022 were enrolled.They were divided into the positive group and the negative group according to whether they carried a TCF3: : PBX1 fusion gene.The clinical characteristics, treatment response, adverse reactions, and prognosis of the 2 groups of patients were analyzed.The rank sum and Kruskal-Wallis tests were used to compare two and more than two groups of numerical variables, respectively.Fisher′s exact test was used to compare categorical variables.Results:Among the 2 164 patients, 116 (5.4%) were TCF3: : PBX1 positive, of which 70 patients were female, accounting for 60.3%.There were 840 female patients in the TCF3: : PBX1-negative group, accounting for 41.0%.There was a significant difference in the ratio of females between the TCF3: : PBX1-positive and TCF3: : PBX1-negative groups ( P<0.001).No significant difference was observed in age of onset between the two groups( P>0.05).The proportion of bone marrow naive cells [54.00 (14.00, 76.50)% vs.29.00 (3.00, 68.00)%], white blood cell counts [25.30 (10.46, 60.94)×10 9/L vs.9.03 (4.38, 30.73)×10 9/L] and hemoglobin counts [82.00(63.00, 101.00) g/L vs.74.00(60.00, 90.00) g/L] in the TCF3: : PBX1-positive group were significantly higher than those in the negative group at the onset (all P<0.05).In terms of treatment response, the proportion of peripheral blood naive cells on Day 8 in the TCF3: : PBX1-positive group was significantly higher than that in the negative group [2.00 (0, 9.00)% vs.0 (0, 2.00)%, P<0.001].The proportion of minimal residual disease <0.1% on Day 15 in the TCF3: : PBX1-positive group was significantly higher than that in the negative group ( P=0.038).There were no significant differences in cumulative recurrence rate, treatment-related mortality (TRM), and overall survival (OS) between the TCF3: : PBX1-positive group and TCF3: : PBX1-negative group (all P>0.05).The cumulative recurrence risk of TCF3: : PBX1-positive patients was 9.646 times higher than that of ETV6: : RUNX1-positive patients with better prognosis( HR=9.646, 95% CI: 1.026-90.700, P=0.047).There were no significant differences in TRM and OS between TCF3: : PBX1-positive and ETV6: : RUNX1-positive patients (all P>0.05).A significant enrichment of PAX5 mutations was detected in TCF3: : PBX1-positive patients.Among the 7 high-risk TCF3: : PBX1-positive patients in a single center, 4 patients had PAX5 mutations, and this proportion was significantly higher than that in other patients ( P<0.001). Conclusions:B-ALL children carrying a TCF3: : PBX1 fusion gene have a high remission rate and good long-term prognosis after intensive chemotherapy.It is suggesting that TCF3: : PBX1-positive B-ALL patients should be rated at intermediate risk to receive intensive chemotherapy.

Objective To investigate the value of serum α-hydroxybutyric dehydrogenase(α-HBDH),cysteine-rich protein 61(CYR61)and gasdermin D(GSDMD)level testing in patients with sepsis-combined cardiomyopathy for clinical diagnosis and prognostic assessment.Methods A total of 244 sepsis patients who underwent consultation and treatment in Baotou Central Hospital from May 2020 to December 2023 were selected as the study subjects,and were separated into a study group(combined cardiomyopathy,n=106)and a control group(uncombined cardiomyopathy,n=138)according to whether they were combined cardiomyopathy or not.The levels of α-HBDH,CYR61 and GSDMD were measured by enzyme linked immunosorbent assay(ELISA)method.Pearson and Spearman methods were used to analyze the correlation of α-HBDH,CYR61,and GSDMD with systolic and diastolic blood pressure,left ventricular ejection fraction(LVEF)and acute physiology and chronic health evaluationⅡ(APACHE II)score.Multifactorial Logistic regression was used to analyze the factors affecting sepsis-combined cardiomyopathy.Receiver operator characteristic(ROC)curves were used to assess the diagnostic value of α-HBDH,CYR61 and GSDMD for sepsis-combined cardiomyopathy and their validity for prognostic prediction.Results Serum α-HBDH(278.35±18.89ng/ml vs 253.47±12.75ng/ml),CYR61(18.23±4.14mg/L vs 14.48±2.67mg/L)and GSDMD(12.39±3.28mg/L vs 9.46±2.17mg/L)levels were higher in the study group compared to the control group,and the differences were statistically significant(t=12.261,8.572,8.377,all P<0.05).The levels of α-HBDH(291.93±19.22ng/ml),CYR61(20.33±3.43mg/L)and GSDMD(14.01±3.09mg/L)were higher in the death patients compared to the survived patients(268.71±13.09ng/ml,16.74±2.88mg/L,11.24±2.55mg/L),and the differences were statistically significant(t=7.402,5.839,5.044,all P<0.05).Correlation analysis showed that α-HBDH,CYR61,and GSDMD were negatively correlated with systolic blood pressure,diastolic blood pressure and LVEF(r=-0.631～-0.422,all P<0.05),α-HBDH,CYR61,GSDMD were negatively correlated with APACHE II score(r=0.531,0.507,0.611,all P<0.05).Multifactorial Logistic regression analysis showed that systolic blood pressure,diastolic blood pressure,and LVEF were protective factors affecting sepsis-combined cardiomyopathy(Wald χ2=6.823,7.986,10.875,all P<0.05),and α-HBDH,CYR61,and GSDMD were risk factors affecting sepsis-combined cardiomyopathy(Wald χ2=9.376,6.849,7.435,all P<0.05).From the ROC curve analysis,it was known that the combined application of α-HBDH,CYR61,and GSDMD was more effective in the diagnosis of sepsis-combined cardiomyopathy(Z=2.369,2.454,2.573),the combined application of α-HBDH,CYR61,and GSDMD were superior for prognostic prediction in sepsis-combined cardiomyopathy(Z=2.352,2.468,2.581),and the differences were statistically significant(all P<0.05).Conclusion Serum α-HBDH,CYR61 and GSDMD levels are increased in patients with sepsis-combined cardiomyopathy,and they are correlated with prognosis.The combination of these three tests has a higher diagnostic value and prognostic value in sepsis combined cardiomyopathy.

Hyperemesis gravidarum(HG)refers to persistent and severe nausea and vomiting during early pregnancy.Severe HG may lead to maternal dehydration,electrolyte imbalances,malnutrition,and even hypotension and arrhythmias,potentially affecting fetal growth and development.Due to the unique physiological state of pregnancy,treatment options for HG are limited.Metoclopramide,has become a commonly used drug in treating HG due to its prove efficacy and safety.Previous studies have primarily focused on the extrapyramidal side effects of metoclopramide,but research on its psychiatric adverse effects,such as mania and somnolence,remains limited,particularly in pregnant patients.This paper reports a case of psychiatric abnormalities in an HG patient following metoclopramide administration.By analyzing the patient's condition,medication use,and adverse reactions,this study explores the potential mechanisms underlying metoclopramide-induced psychiatric abnormalities and provides clinical recommendations for preventing and managing such psychiatric adverse effects during pregnancy.These findings offer valuable guidance for healthcare professionals regarding the appropriate use of this medication.

Objective:To investigate the clinical efficacy of insulin combined with zoledronic acid in the treatment of type 2 diabetes mellitus (T2DM) complicated by osteoporosis and its effects on bone metabolism and pancreatic β-cell function.Methods:A retrospective analysis was conducted on the clinical data of 68 patients with T2DM complicated by osteoporosis who were treated at Wenling Hospital of Traditional Chinese Medicine from January 2021 to December 2023. The patients were divided into a control group and a study group, with 34 cases in each group. The control group received treatment with zoledronic acid combined with acarbose, while the study group received insulin combined with zoledronic acid. The clinical efficacy and improvements in bone metabolism (bone-specific alkaline phosphatase, alkaline phosphatase, osteoprotegerin), bone density, and pancreatic β-cell function (homeostasis model assessment of beta-cell function and homeostasis model assessment of insulin resistance) were evaluated and compared between the two groups. Additionally, the incidence of adverse reactions was also compared between the two groups.Results:The clinical overall effective rate in the study group was significantly higher than that in the control group [91.18% (31/34) vs. 67.65% (23/34), χ2 = 5.76, P < 0.05]. The levels of bone-specific alkaline phosphatase [(44.92 ± 5.92) μg/L], alkaline phosphatase [(109.12 ± 9.46) U/L], and osteoprotegerin [(331.42 ± 13.92) ng/L]in the study group were significantly higher than those in the control group [(38.25 ± 4.78) μg/L, (102.95 ± 9.23) U/L, (312.26 ± 13.11) ng/L, t = -5.11, -2.72, -5.84, all P < 0.05]. After treatment, the bone density indicators in the study group [(0.80 ± 0.12) g/cm2, (0.84 ± 0.13) g/cm2, (0.82 ± 0.10) g/cm2, (0.83 ± 0.11) g/cm2]were significantly higher than those in the control group [(0.72 ± 0.11) g/cm2, (0.73 ± 0.09) g/cm2, (0.71 ± 0.12) g/cm2, (0.74 ± 0.09) g/cm2, t = -2.87, -7.38, -4.11, -3.69, all P < 0.05]. The homeostasis model assessment of beta-cell function and homeostasis model assessment of insulin resistance in the study group were (54.97 ± 5.42) and (1.61 ± 0.89), respectively, which were significantly different from those in the control group [(43.11 ± 5.23), (2.46 ± 0.96), t = -25.97, 3.79, both P < 0.05]. There was no statistically significant difference in the incidence of adverse reactions between the two groups ( χ2 = 0.36, P > 0.05). Conclusions:Insulin combined with zoledronic acid can enhance clinical efficacy in patients with T2DM complicated by osteoporosis, improve bone metabolism, boost pancreatic β-cell function, and demonstrate good safety.

Bispecific antibodies(BsAbs),as an important recent innovation in the field of tumor immunotherapy in recent years,can simultaneously or sequentially target different antigens or two different epitopes of the same antigen.Compared with traditional monoclonal antibodies,they can produce superior therapeutic effects.This article reviews the progress in clinical applications and safety research of BsAbs in cancer therapy,revealing that they(such as blinatumomab,glofitamab,teclistamab,amivantamab,etc.)exhibit significant therapeutic efficacy against hematological malignancies,lung cancer,cervical cancer,melanoma,and other cancers.For cytokine release syndrome(CRS)induced by BsAbs,prophylactic or pre-emptive medication is commonly administered in clinical practice;for neurotoxicity and infections triggered by BsAbs,clinical practice necessitates rigorous monitoring of patients'vital signs and the provision of essential treatments.In addition,different BsAbs exhibit variations in escalation dose,infusion rate,storage duration,and equipment requirements.Therefore,strict adherence to the instructions in the drug package inserts is essential during clinical operations to ensure safety and therapeutic efficacy.In the future,more multicenter trials need to be conducted to validate the efficacy and safety of BsAbs across different tumor types and patient populations,and long-term follow-up data should be accumulated to optimize treatment cycles and dosage regimens.

Objective To investigate the value of serum α-hydroxybutyric dehydrogenase(α-HBDH),cysteine-rich protein 61(CYR61)and gasdermin D(GSDMD)level testing in patients with sepsis-combined cardiomyopathy for clinical diagnosis and prognostic assessment.Methods A total of 244 sepsis patients who underwent consultation and treatment in Baotou Central Hospital from May 2020 to December 2023 were selected as the study subjects,and were separated into a study group(combined cardiomyopathy,n=106)and a control group(uncombined cardiomyopathy,n=138)according to whether they were combined cardiomyopathy or not.The levels of α-HBDH,CYR61 and GSDMD were measured by enzyme linked immunosorbent assay(ELISA)method.Pearson and Spearman methods were used to analyze the correlation of α-HBDH,CYR61,and GSDMD with systolic and diastolic blood pressure,left ventricular ejection fraction(LVEF)and acute physiology and chronic health evaluationⅡ(APACHE II)score.Multifactorial Logistic regression was used to analyze the factors affecting sepsis-combined cardiomyopathy.Receiver operator characteristic(ROC)curves were used to assess the diagnostic value of α-HBDH,CYR61 and GSDMD for sepsis-combined cardiomyopathy and their validity for prognostic prediction.Results Serum α-HBDH(278.35±18.89ng/ml vs 253.47±12.75ng/ml),CYR61(18.23±4.14mg/L vs 14.48±2.67mg/L)and GSDMD(12.39±3.28mg/L vs 9.46±2.17mg/L)levels were higher in the study group compared to the control group,and the differences were statistically significant(t=12.261,8.572,8.377,all P<0.05).The levels of α-HBDH(291.93±19.22ng/ml),CYR61(20.33±3.43mg/L)and GSDMD(14.01±3.09mg/L)were higher in the death patients compared to the survived patients(268.71±13.09ng/ml,16.74±2.88mg/L,11.24±2.55mg/L),and the differences were statistically significant(t=7.402,5.839,5.044,all P<0.05).Correlation analysis showed that α-HBDH,CYR61,and GSDMD were negatively correlated with systolic blood pressure,diastolic blood pressure and LVEF(r=-0.631～-0.422,all P<0.05),α-HBDH,CYR61,GSDMD were negatively correlated with APACHE II score(r=0.531,0.507,0.611,all P<0.05).Multifactorial Logistic regression analysis showed that systolic blood pressure,diastolic blood pressure,and LVEF were protective factors affecting sepsis-combined cardiomyopathy(Wald χ2=6.823,7.986,10.875,all P<0.05),and α-HBDH,CYR61,and GSDMD were risk factors affecting sepsis-combined cardiomyopathy(Wald χ2=9.376,6.849,7.435,all P<0.05).From the ROC curve analysis,it was known that the combined application of α-HBDH,CYR61,and GSDMD was more effective in the diagnosis of sepsis-combined cardiomyopathy(Z=2.369,2.454,2.573),the combined application of α-HBDH,CYR61,and GSDMD were superior for prognostic prediction in sepsis-combined cardiomyopathy(Z=2.352,2.468,2.581),and the differences were statistically significant(all P<0.05).Conclusion Serum α-HBDH,CYR61 and GSDMD levels are increased in patients with sepsis-combined cardiomyopathy,and they are correlated with prognosis.The combination of these three tests has a higher diagnostic value and prognostic value in sepsis combined cardiomyopathy.

Hyperemesis gravidarum(HG)refers to persistent and severe nausea and vomiting during early pregnancy.Severe HG may lead to maternal dehydration,electrolyte imbalances,malnutrition,and even hypotension and arrhythmias,potentially affecting fetal growth and development.Due to the unique physiological state of pregnancy,treatment options for HG are limited.Metoclopramide,has become a commonly used drug in treating HG due to its prove efficacy and safety.Previous studies have primarily focused on the extrapyramidal side effects of metoclopramide,but research on its psychiatric adverse effects,such as mania and somnolence,remains limited,particularly in pregnant patients.This paper reports a case of psychiatric abnormalities in an HG patient following metoclopramide administration.By analyzing the patient's condition,medication use,and adverse reactions,this study explores the potential mechanisms underlying metoclopramide-induced psychiatric abnormalities and provides clinical recommendations for preventing and managing such psychiatric adverse effects during pregnancy.These findings offer valuable guidance for healthcare professionals regarding the appropriate use of this medication.

Objective:To investigate the clinical efficacy of insulin combined with zoledronic acid in the treatment of type 2 diabetes mellitus (T2DM) complicated by osteoporosis and its effects on bone metabolism and pancreatic β-cell function.Methods:A retrospective analysis was conducted on the clinical data of 68 patients with T2DM complicated by osteoporosis who were treated at Wenling Hospital of Traditional Chinese Medicine from January 2021 to December 2023. The patients were divided into a control group and a study group, with 34 cases in each group. The control group received treatment with zoledronic acid combined with acarbose, while the study group received insulin combined with zoledronic acid. The clinical efficacy and improvements in bone metabolism (bone-specific alkaline phosphatase, alkaline phosphatase, osteoprotegerin), bone density, and pancreatic β-cell function (homeostasis model assessment of beta-cell function and homeostasis model assessment of insulin resistance) were evaluated and compared between the two groups. Additionally, the incidence of adverse reactions was also compared between the two groups.Results:The clinical overall effective rate in the study group was significantly higher than that in the control group [91.18% (31/34) vs. 67.65% (23/34), χ2 = 5.76, P < 0.05]. The levels of bone-specific alkaline phosphatase [(44.92 ± 5.92) μg/L], alkaline phosphatase [(109.12 ± 9.46) U/L], and osteoprotegerin [(331.42 ± 13.92) ng/L]in the study group were significantly higher than those in the control group [(38.25 ± 4.78) μg/L, (102.95 ± 9.23) U/L, (312.26 ± 13.11) ng/L, t = -5.11, -2.72, -5.84, all P < 0.05]. After treatment, the bone density indicators in the study group [(0.80 ± 0.12) g/cm2, (0.84 ± 0.13) g/cm2, (0.82 ± 0.10) g/cm2, (0.83 ± 0.11) g/cm2]were significantly higher than those in the control group [(0.72 ± 0.11) g/cm2, (0.73 ± 0.09) g/cm2, (0.71 ± 0.12) g/cm2, (0.74 ± 0.09) g/cm2, t = -2.87, -7.38, -4.11, -3.69, all P < 0.05]. The homeostasis model assessment of beta-cell function and homeostasis model assessment of insulin resistance in the study group were (54.97 ± 5.42) and (1.61 ± 0.89), respectively, which were significantly different from those in the control group [(43.11 ± 5.23), (2.46 ± 0.96), t = -25.97, 3.79, both P < 0.05]. There was no statistically significant difference in the incidence of adverse reactions between the two groups ( χ2 = 0.36, P > 0.05). Conclusions:Insulin combined with zoledronic acid can enhance clinical efficacy in patients with T2DM complicated by osteoporosis, improve bone metabolism, boost pancreatic β-cell function, and demonstrate good safety.